Several studies also report that CyPJ is upregulated in human glioma (Qi et al., 2005), estrogen receptor-negative breast cancer (Couch et al., 2016), and primary gastric adenocarcinoma (Gong et al., 2017), suggesting that the CyPJ enzyme may be an important and potential therapeutic target. The gene discussed is PPIL3; the disease is gastric adenocarcinoma.